Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.695 USD | +7.10% | +4.97% | -1.20% |
Financials (USD)
Sales 2024 * | 5.82M | Sales 2025 * | 5.39M | Capitalization | 419M |
---|---|---|---|---|---|
Net income 2024 * | -201M | Net income 2025 * | -224M | EV / Sales 2024 * | 32.6 x |
Net cash position 2024 * | 229M | Net cash position 2025 * | 153M | EV / Sales 2025 * | 49.4 x |
P/E ratio 2024 * |
-2.07
x | P/E ratio 2025 * |
-2.06
x | Employees | 181 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.42% |
Latest transcript on Fate Therapeutics, Inc.
1 day | +7.10% | ||
1 week | +4.97% | ||
Current month | +0.41% | ||
1 month | -9.66% | ||
3 months | -52.26% | ||
6 months | +39.43% | ||
Current year | -1.20% |
Managers | Title | Age | Since |
---|---|---|---|
J. Wolchko
FOU | Founder | 53 | 07-04-26 |
Edward Dulac
DFI | Director of Finance/CFO | 49 | 20-08-16 |
Chairman | 75 | 11-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Epstein
BRD | Director/Board Member | 58 | 14-03-16 |
Robert Hershberg
BRD | Director/Board Member | 61 | 20-04-30 |
Tim Coughlin
BRD | Director/Board Member | 57 | 13-07-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.95% | 0 M€ | -.--% | - | |
2.10% | 1 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 3.68 | +6.67% | 3,629,455 |
24-05-30 | 3.45 | +0.58% | 1,508,044 |
24-05-29 | 3.43 | -3.11% | 2,907,515 |
24-05-28 | 3.54 | +0.57% | 1,699,730 |
24-05-24 | 3.52 | +2.62% | 1,257,549 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.20% | 419M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- FATE Stock